文献速递临床免疫临床微生物

半乳甘露聚糖化学发光免疫分析法诊断血液病患者肺曲霉病的多中心验证

Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease.
PubMed 文献 · J Clin Microbiol · 2025-01-21

该研究在血液病患者中比较VirCLIA化学发光免疫分析法与Platelia ELISA检测血清半乳甘露聚糖诊断侵袭性曲霉病的效能,两个独立队列分别纳入161例和189例患者,显示CLIA与ELISA性能相当,建议高验前概率患者采用0.100作为CLIA阳性 cutoff。

要点

  • VirCLIA与Platelia ELISA在血液病患者血清半乳甘露聚糖检测中性能相当。
  • 高验前概率患者建议采用0.100作为VirCLIA的阳性 cutoff。
  • 两种方法敏感度均仅为低至中等水平。

核心结论

  • VirCLIA化学发光免疫分析法与Platelia ELISA在血液病患者血清半乳甘露聚糖检测中性能相当。
  • 在高验前概率患者中,建议采用0.100作为VirCLIA的阳性 cutoff。
  • 两种方法的敏感度均仅为低至中等水平。

研究设计与样本

  • 多中心研究,第一队列纳入4个中心161例疑似侵袭性曲霉病的血液病患者。
  • 第二独立队列纳入4个中心189例患者,验证最佳 cutoff。
  • 患者按EORTC/MSGERC 2020标准分为确诊/临床诊断侵袭性曲霉病和可能/无侵袭性曲霉病。

主要发现

  • 第一队列中,ELISA(1.0 cutoff)敏感度和特异度分别为21.1%和100.0%,ELISA(0.5 cutoff)为36.6%和95.6%,CLIA(0.200 cutoff)为11.3%和97.8%。
  • 第二队列中,ELISA(≥1.0)和CLIA(≥0.200)敏感度相当(33.3% vs 38.1%)。
  • 第一队列CLIA的ROC曲线下面积低于ELISA(65.0% vs 78.7%,P=0.005),第二队列两者相当(79.5% vs 81.3%,P=0.649)。
  • Youden指数确定0.100为CLIA最佳 cutoff,两个队列敏感度分别为35.2%和61.9%,特异度略降至85.6%和90.5%。

关键数值与推荐

  • VirCLIA制造商 cutoff 为0.200。
  • Youden指数确定的最佳CLIA cutoff为0.100。
  • 第一队列CLIA(0.200 cutoff)敏感度11.3%、特异度97.8%。
  • 第二队列CLIA(0.200 cutoff)敏感度38.1%。
  • 高验前概率患者建议CLIA cutoff为0.100。

临床怎么用

  • 在血液病患者中可使用VirCLIA检测血清半乳甘露聚糖辅助诊断侵袭性曲霉病。
  • 对高验前概率患者,建议将VirCLIA阳性 cutoff 设为0.100以提高敏感度。
  • 结果解读时应结合临床验前概率,因两种方法敏感度均有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An accurate diagnosis of invasive aspergillosis (IA) in patients with underlying hematological malignancies relies heavily on galactomannan detection. In this study, we compared the VirCLIA chemiluminescence immunoassay (CLIA) with the frequently used Platelia enzyme-linked immunosorbent assay (ELISA) on serum from hematology patients with suspected IA. Patients were categorized according to EORTC/MSGERC 2020 definitions into proven/probable IA and possible/no IA. The first cohort included 161 patients at four centers, and the VirCLIA manufacturer's cutoff of 0.200 was evaluated. Next, the optimal cutoff was determined using the Youden's index. In a second independent cohort of 189 patients from four centers, this optimal cutoff was evaluated again. In the first cohort, sensitivities and specificities for probable/proven IA were 21.1% and 100.0% for ELISA (1.0 cutoff) and 36.6% and 95.6% (0.5 cutoff), compared to 11.3% and 97.8% for CLIA (0.200 cutoff). In the second cohort, the sensitivities of ELISA and CLIA were comparable (ELISA ≥ 1.0: 33.3%, CLIA ≥ 0.200: 38.1%). The area under the ROC curve was lower for CLIA than for ELISA in the first cohort (65.0% vs 78.7%, P = 0.005) but comparable in the second cohort (79.5% vs 81.3%, P = 0.649). Youden's index identified 0.100 as the optimal CLIA cutoff with sensitivities of 35.2% and 61.9% in cohorts 1 and 2, respectively, at slightly reduced specificities of 85.6% and 90.5%. While the sensitivity of both assays was low to moderate at best, in patients with a high pre-test probability, we suggest 0.100 as the cutoff for the VirCLIA assay.IMPORTANCEThis study demonstrates a comparable performance of the novel chemiluminescence immunoassay (CLIA) and the conventionally used enzyme-linked immunosorbent assay for galactomannan serum testing in hematological patients at high risk for invasive aspergillosis. In patients with a high pre-test probability, a lower CLIA cutoff of 0.100 is preferred.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Lamberink H, Huygens S, Aerts R, et al. Multicenter validation of a galactomannan chemiluminescence immunoassay for the diagnosis of pulmonary aspergillosis on serum of patients with hematological disease. J Clin Microbiol. 2025. PMID: 39835823. doi:10.1128/jcm.01053-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。